Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Does Bristol Nuc’s Possible Cardiac Toxicity Portend A Class Effect?

Executive Summary

Bristol-Myers Squibb has halted study of its Phase II nucleoside polymerase inhibitor for hepatitis C due to one trial patient suffering heart failure. It remains unclear if that event is related to the study drug, but do repeated toxicity issues with “nucs” indicate a class effect?


Related Content

With FDA Hold Continuing, Idenix To Focus On NS5A Inhibitor And New Uridine Nucleosides
Gilead Already Seeking Stribild Successor, Going Solo On Key HCV Combo
Cruel Summer: High-Profile Trial Failures Dominate R&D News Flow
Hep C Nucleoside Scare: FDA Wants Idenix’s CV Safety Data After BMS Event
Financings Of The Fortnight: Idenix To Forge Ahead On HCV Combo After Novartis’ Departure
Cruel Summer: High-Profile Trial Failures Dominate R&D News Flow
HCV Buyup Continues As Bristol Offers $2.5 Billion For Inhibitex
Gilead Goes For The Gold (Standard) In Plan To Acquire HCV Specialist Pharmasset
Roche’s HCV Changes Boost Pharmasset Compound
Idenix Focusing On HIV Program, Tyzeka Launch Following Clinical Hold On Hep C Candidate


Related Companies




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts